Why Insulet’s recent selloff has investors reassessing the stock
Recent debate around Insulet (PODD) has been driven by a sharp pullback in the share price following strong annual revenue and net income, prompting fresh questions about how the Omnipod business is being valued.
See our latest analysis for Insulet.
At a recent share price of US$156.89, Insulet’s 7 day share price return of 5.52% has not offset a 30 day share price decline of 18.43% and a 1 year total shareholder return decline of 51.12%. This suggests momentum has weakened as investors reassess growth expectations and risk around Omnipod.
If this reassessment of Insulet has you rethinking your sector exposure, it can be helpful to scan for other healthcare stocks using artificial intelligence as a growth driver through our 33 healthcare AI stocks.
So with Insulet trading well below some valuation estimates and recent returns under pressure, is the stock now offering a margin of safety, or is the market already baking in realistic expectations for Omnipod’s future growth?
Most Popular Narrative: 51.9% Undervalued
Against the last close of $156.89, the most widely followed narrative places Insulet’s fair value much higher, framing recent weakness as a gap between price and long term expectations.
Rapidly rising adoption of Omnipod 5 in both the U.S. and international markets, driven by strong clinical evidence, ease of use, and superior integration with the latest glucose sensors, is positioning Insulet to capture a disproportionately large share of the expanding global diabetes device market, supporting outsized top-line revenue growth for several years.
Want to see what is behind that confidence in Omnipod 5 and new geographies? The narrative relies on ambitious revenue, margin and future earnings assumptions that are all tied back to a single discounted cash flow model using a 7.98% discount rate.
Result: Fair Value of $326.35 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this optimistic setup still hinges on Omnipod remaining competitive against rising patch pump rivals, as well as on new manufacturing and international investments earning their keep.
Find out about the key risks to this Insulet narrative.
Next Steps
Seen enough to form a view, or still on the fence given the mix of concern and optimism around Omnipod and future growth drivers? Act while the information is fresh and compare the bull and bear points with our breakdown of 2 key rewards and 1 important warning sign.
Looking for more investment ideas?
If you stop with just one stock, you risk missing other opportunities that better match your goals, risk comfort and income needs, so keep widening your watchlist.
- Spot potential value opportunities early by scanning a curated set of companies using our screener containing 20 high quality undiscovered gems.
- Strengthen the quality of your portfolio by focusing on companies highlighted in the solid balance sheet and fundamentals stocks screener (46 results).
- Target income focused opportunities by reviewing the 10 dividend fortresses that could complement your growth holdings with regular cash returns.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com